Preview REPORT Cannabis Extracts in Germany 2021-2025

4 Executive Summary Cannabis extracts, with their cannabinoids, flavones and terpenes, are preparing to replace Cannabis flowers as the most important prescription medicine. The first three years after the Cannabis Act came into force in 2017 were characterised by the prescription of Cannabis flow- ers. In 2020, the Cannabis flower submarket stagnated for the first time and extracts were made available more frequently. In 2021, we see more than 30 different Cannabis extracts from more than 14 different suppliers in the LAUER-tax already in the first quarter. Over the year, availability will increase to perhaps more than 50 different extracts. Cannabis extracts are characterised on the one hand by the relation of the two main cannabinoids (THC and CBD) and on the other hand by their terpene spectrum. Which Cannabis extracts will prevail in the market is an exciting question. Answers to this question can be found in the report "the market for Cannabis extracts in Germany 2021 - 2025". EPC HealthCare GmbH in Bremen, in close cooperation with the leading data service pro- vider for the pharmaceutical industry in Germany, INSIGHT Health GmbH & Co. KG from Wal- dems-Esch, has produced the first business report - the market for Cannabis extracts in Ger- many 2021 - 2025. First, the basics of cultivation and especially the cultivation of Cannabis flowers are pre- sented, as well as the influences of the genetics of the plants on the content of cannabinoids, because they form the precious raw material for the production of extracts. Subsequently, the pharmacology and pharmacokinetics of Cannabis extracts are briefly explained. The relevant legal bases are presented. The regulation of Cannabis extracts in Germany concludes the in- troductory chapters. The market review starts with the requirements for the preparation of prescriptions with Cannabis extracts as the main ingredient in the pharmacy. The monograph Cannabis Extract and the requirements for identity verification in the pharmacy are reported. The business report then spans a wide range of topics to examine the Cannabis extract market from key perspectives. Quantitative market data are put in relation to qualitative data from a 360° market research with doctors, pharmacists, patients as well as the payers in the SHI and PHI system. The market for Cannabis extracts is presented by segments (extracts with high THC content, with low THC content and balanced proportions of THC and CBD) from a national and also regional perspective. The suppliers of Cannabis extracts in Germany will get their products exclusively from abroad until 2020. A large part obtains the Cannabis extracts from Canada. Other relevant quantities now come from Australia. Imports from Israel, other EU countries or South America do not yet play a relevant role. Regarding the pricing of Cannabis extracts, a relatively high average price is to be expected. Since the payers have not linked the reimbursement to the quantity of the ingredients, but to the volume (ml) and have also tied the surcharges to a reimbursement limit, there will be a clear price sensitivity relatively soon.